A Double-Blind Placebo-Controlled Asian Study of Atomoxetine Hydrochloride in the Treatment of Adult Patients with Attention-Deficit/Hyperactivity Disorder (ADHD)

A Double-Blind Placebo-Controlled Asian Study of Atomoxetine Hydrochloride in the Treatment of Adult Patients with Attention-Deficit/Hyperactivity Disorder (ADHD) - A Double-Blind Placebo-Controlled Asian Study of Atomoxetine Hydrochloride in the Treatment of Adult Patients with Attention-Deficit/Hyperactivity Disorder (ADHD)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002806

Enrollment

209

Registered

2009-11-27

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention-Deficit/Hyperactivity Disorder (ADHD)

Interventions

atomoxetine treatment group (40-120 mg/day after the breakfast), double blind study (12 weeks) control (placebo) group (after the breakfast), double blind study (12 weeks)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Individuals with attention-deficit/ hyperactvity disorder according to DSM-IV

Exclusion criteria

Exclusion criteria: Individuals with major depression or sucidal attempt

Design outcomes

Primary

Measure	Time frame
CAARS-Inv	—

Secondary

Measure	Time frame
AAQOL, EQ-5D	—

Countries

Japan,Asia(except Japan)

Contacts

Public ContactTakashi Okada

Kyoto University Hospital Day Care Unit

kyopsy@kuhp.kyoto-u.ac.jp075-751-3384

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026